Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico A nationwide descriptive study

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico : A nationwide descriptive study

Copyright © 2021 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 229(2021) vom: 10. Aug., Seite 108786
1. Verfasser: García-Grimshaw, Miguel (VerfasserIn)
Weitere Verfasser: Ceballos-Liceaga, Santa Elizabeth, Hernández-Vanegas, Laura E, Núñez, Isaac, Hernández-Valdivia, Noé, Carrillo-García, Daniel Amado, Michel-Chávez, Anaclara, Galnares-Olalde, Javier Andrés, Carbajal-Sandoval, Guillermo, Del Mar Saniger-Alba, María, Carrillo-Mezo, Roger A, Fragoso-Saavedra, Sergio, Espino-Ojeda, Alba, Blaisdell-Vidal, Carlos, Mosqueda-Gómez, Juan Luis, Sierra-Madero, Juan, Pérez-Padilla, Rogelio, Alomía-Zegarra, José Luis, López-Gatell, Hugo, Díaz-Ortega, José Luis, Reyes-Terán, Gustavo, Arauz, Antonio, Valdés-Ferrer, Sergio Iván
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2021
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Observational Study Adverse event BNT162b2 COVID-19 SARS-CoV-2 Vaccine COVID-19 Vaccines Vaccines, Synthetic BNT162 Vaccine N38TVC63NU
Beschreibung
Zusammenfassung:Copyright © 2021 Elsevier Inc. All rights reserved.
mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform
Beschreibung:Date Completed 12.08.2021
Date Revised 13.12.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2021.108786